Category Archives: Uncategorized

Antibody–drug conjugates (ADCs) are an emerging class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. The choice of tumor cell surface antigen is critical to ADC efficacy and safety, influencing drug delivery, internalization, and off-target toxicity. This article reviews key tumor-associated antigens commonly targeted in […]

Monoclonal Antibodies, This review commemorates the 50-year evolution of monoclonal antibodies (mAbs), tracing their transformation from murine hybridoma-derived research tools to a central pillar of clinical medicine. The authors chronicle major milestones in antibody engineering, including chimeric, humanized, and fully human formats, and discuss how technological innovations have addressed immunogenicity, pharmacokinetics, and efficacy challenges. The […]

Beyond Hypertension Angiotensin receptor blockers (ARBs) have long been established as effective treatments for hypertension through selective blockade of the angiotensin II type 1 (AT1) receptor. However, emerging research has revealed their broader therapeutic potential across cardiovascular, neurological, metabolic, and inflammatory diseases. By modulating local renin–angiotensin system activity and shifting signaling toward protective AT2 receptor […]

Gepotidacin, branded as Blujepa, is a groundbreaking antibiotic approved by the FDA in 2025 for the treatment of uncomplicated urinary tract infections and gonorrhea. As the first in a new class of topoisomerase inhibitors, Gepotidacin offers a unique mechanism of action that addresses rising antimicrobial resistance. Clinical trials demonstrated strong efficacy and safety, positioning the […]

Telisotuzumab vedotin-tllv (EMRELIS™) is an FDA-approved antibody-drug conjugate for adults with c-MET–positive advanced non-small cell lung cancer (NSCLC) who have progressed after prior systemic therapy. By combining a monoclonal antibody targeting the c-MET receptor with a cytotoxic payload (MMAE), EMRELIS™ delivers targeted cell killing with reduced systemic toxicity. Clinical trials have shown high objective response […]

PEI Transfection Reagents: Polyethylenimine (PEI) is one of the most widely used non-viral transfection reagents for gene delivery in mammalian cells. Its unique cationic structure enables efficient condensation of nucleic acids, cellular uptake, and gene expression through mechanisms such as the debated “proton sponge” effect. Both linear and branched PEI formulations have been developed, with […]

Antibody–drug conjugates (ADCs) represent one of the most promising advances in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic agents. Central to their success is the linker chemistry, which dictates stability in circulation, controlled drug release, and therapeutic efficacy. This blog explores the evolution of ADC linker strategies, from […]

Lactobacillus reuteri is a probiotic bacterium with scientifically supported benefits for digestive, immune, and mental health. This blog post explores its mechanisms of action, including antimicrobial production, gut barrier support, and interaction with the gut-brain axis. Readers will learn about specific L. reuteri strains (such as DSM 17938 and ATCC PTA 6475), their unique functions, […]

Histone deacetylase (HDAC) inhibitors have emerged as pivotal agents in epigenetic therapy, primarily used in hematologic malignancies due to the toxicity profiles of early-generation pan-inhibitors. Recent advances in isoform-selective HDAC inhibitors, PROTAC degraders, and innovative combination strategies have redefined the therapeutic landscape, especially in solid tumors. This article reviews the clinical evolution, mechanistic insights, biomarker […]